Clinical study of pazufloxacin mesilate in obstetric and gynecological infections penetrating the genital tissues and retroperitoneal exudate.
|
Accession number;00A0829648
|
| Title;Clinical study of pazufloxacin mesilate in obstetric and gynecological infections penetrating the genital tissues and retroperitoneal exudate. |
| Author;
MATSUDA SEIJI
(Koto Hosp.)
ISHIKAWA MUTSUO
(Asahikawa Med. Coll.)
HAGA HIROMITSU
(Asahikawa Red Cross Hosp.)
CHIMURA TETSURO
(Shirataka-choritsu Byoin)
SAITO NORIYASU
(Tsuruoka City Shonai Hosp.)
NUMAZAKI MASAYOSHI
(Nagai City Gen. Hosp.)
WADA YUICHI
(Sendai Natl. Hosp.)
MITSUHASHI NAOKI
(Juntendo Univ. School of Medicine, Juntendo Hosptal)
NAMBA KATSUTOSHI
(Fukuyama National Hospital)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.48;NO.8;PAGE.654-672(2000)
|
| Figure&Table&Reference;FIG.3, TBL.18, REF.18 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Pazufloxacin mesilate (PZFX mesilate, T-3762), a newly developed intravenous fluoroquinolone antibacterial agent, was clinically evaluated for use against obstetric and gynecological infections, that have penetrated the genital tissues and retroperitoneal exudate. The following results were obtained. 1. A drip infusion of 300 mg over a period of 30 minutes was given to ten patients scheduled for a radical hysterectomy. PZFX concentrations in the serum, genital tissues (portio vaginalis, cervix uteri, endometrium, myometrium, oviduct, ovary), and retroperitoneal exudate were measured at periodic intervals. 1) In cases 1-5, the concentrations of PZFX in the serum and genital tissues peaked at 0.83 hours after administration. The concentrations of PZFX in the uterine artery blood and the peripheral vein blood were 6.72 .MU.g/mL and 6.21 .MU.g/mL, respectively, at 0.83 hours. The maximum PZFX concentrations were 5.00 .MU.g/g in the portio vaginalis, 7.79 .MU.g/g in the cervix uteri, 13.9 .MU.g/g in the endometrium, 12.9 .MU.g/g in the myometrium, 9.34 .MU.g/g in the oviduct and 5.65 .MU.g/g in the ovaryies. 2) In cases 6-10, the serum PZFX concentrations peaked at 0.25 to 0.5 hours, and the retroperitoneal exudate PZFX concentrations peaked 1 to 4 hours after administration. The mean maximum serum concentration and retroperitoneal exudate concentration were 7.83 .MU.g/mL and 3.18 .MU.g/mL, respectively. 2. Three hundred milligrams or 500 mg of PZFX mesilate was administered to 49 patients with adnexitis, parametritis or pelvic peritonitis two or three times a day for 7 days. 1) The clinical efficacy of the PZFX treatment in 42 patients who qualified for evaluation was evaluated as excellent in 4 patients, good in 33 patients and poor in 5 patients. The overall rate of clinical efficacy was 88.1% (37/42).... (author abst.) |
|
|
|
Related Articles;
|
|
